Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of GB-0895 add-on therapy in uncontrolled severe asthma
MOH_2026-06-07_016866Phase 3Not yet recruiting
- Sponsor
- Generate Biomedicines
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in severe asthma and asthma comparing GB-0895 with Placebo (2 arms). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GB-0895
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on MOH_2026-06-07_016866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-07_016866.